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and C termini at the base of the domain. We previously
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1The Burnham Institute point mutations [5]. A second class of point mutations
10901 North Torrey Pines Road (type IIb), which occur naturally in patients with the blood
La Jolla, California 92037 disorder von Willebrand disease, are “gain of function”
2 Washington University Medical School [6]; that is, they produce a phenotype in which regulation
660 South Euclid Avenue is lost: the mutant full-length vWF is constitutively active
St. Louis, Missouri 63110 and binds platelets in the absence of shear forces. These
3 Thrombosis Research Section sites of mutation map to the lower surface of the domain,
Baylor College of Medicine distal to the GpIb binding surface, and cluster at or near
One Baylor Plaza the disulfide linkage and the interface between the base
Houston, Texas 77030 of the domain and the N- and C-terminal arms. These
mutations increase the affinity of recombinant A1 for
GpIb substantially; for example, the Kd decreases by a
factor of 20, from 3.3 M for wild-type A1 to 160 nMSummary
for the type IIb mutant R545A [7]. In vitro, mutation or
chemical reduction of the disulfide bridge has a similarThe A1 domain of von Willebrand factor (vWF) medi-
ates platelet adhesion to sites of vascular injury by effect. Thus, the affinity for GpIb appears to be regulated
binding to the platelet receptor glycoprotein Ib (GpIb), allosterically, although the nature of the conformational
an interaction that is regulated by hydrodynamic shear changes linking the regulatory and ligand binding sur-
forces. The GpIb binding surface of A1 is distinct from faces is poorly understood.
a regulatory region, suggesting that ligand binding is The three-dimensional structure of the A1 domain is
controlled allosterically. Here we report the crystal closely superposable with the integrin I domain, and
structures of the “gain-of-function” mutant A1 domain both the ligand binding surfaces and regulatory regions
(I546V) and its complex with the exogenous activator are also closely analogous, raising the possibility that
botrocetin. We show that botrocetin switches the mu- the pathways of regulation are similar [4]. In the integrins,
tant A1 back toward the wild-type conformation, sug- conformational changes are transmitted from the ligand
gesting that affinity is enhanced by augmenting the binding surface to the regulatory region via a large shift
GpIb binding surface rather than through allosteric of the C-terminal helix that changes the shape and
control. Functional studies of platelet adhesion under charge distribution of the ligand binding surface [8].
flow further suggest that the activation mechanism is Such a conformational switch is sterically feasible in the
distinct from that of the gain-of-function mutation. A1 domain, and would be consistent with the location
of the type IIb mutations, which cluster around this helix.
Introduction On the basis of the structure of the type IIb mutant I546V,
Celikel et al. have proposed a much smaller conforma-
von Willebrand factor (vWF) is a multidomain, multimeric tional change underlying affinity regulation, involving the
protein that is required for hemostasis in vessels such insertion of a water molecule into the domain core and
as arterial capillaries, where rapid blood flow creates a switch in conformation of the B-C loop [9].
high hydrodynamic shear forces near the vessel wall. vWF binding activity can also be affected by exoge-
The adhesive properties of vWF are tightly regulated, nous modulators, including the snake venom protein
such that plasma vWF does not normally interact with botrocetin [10]. Botrocetin forms a tight binary complex
circulating platelets. At sites of vascular injury, however, with the A1 domain, with a Kd of 23 nM [7] that in-
vWF attaches to exposed collagen via its A3 domain. creases the affinity for GpIb 300-fold from 3.3 M to
Under the influence of shear forces, the newly immobi- 12 nM, leading to platelet agglutination in the absence of
lized vWF is then able to bind to the glycoprotein Ib shear forces. In order to better understand the structural
(GpIb) receptor on platelets via its A1 domain, resulting basis of affinity modulation in vWF, we have determined
in attachment and translocation of platelets, and ulti- the crystal structures of a gain-of-function type IIb mu-
mately thrombus formation [1]. In vitro, recombinant A1 tant of the A1 domain and its complex with botrocetin,
domain immobilized on a solid support recapitulates and correlate them with functional studies on platelet
this phenomenon [2]. interactions under shear stress. Our results reveal the
Although the structure of the A1 domain is known [3, structural basis of activation by botrocetin, and suggest
4], little is known about the structural basis of its affinity that the mechanism is quite distinct from that of the
modulation. The A1 domain comprises a Rossmann-like type IIb mutation.
fold, with a central, mostly parallel  sheet flanked on
both sides by  helices. A disulfide bridge links the N
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Figure 1. Conformational Changes in the A1
Domain
(A) Stereo view of the B-C turn. Uncom-
plexed (blue) and complexed (green) mutant
domains are superimposed onto the wild-
type structure (red). On binding botrocetin,
the mutant’s peptide plane between Asp 560
and Gly 561 flips back to a conformation simi-
lar to that of the wild-type.
(B) Stereo view of the final |2Fc  Fc| map of
the B-C turn in the uncomplexed mutant
A1.
(C) Stereo view of the final |2Fc  Fc| map in
the complexed mutant A1. Maps are con-
toured at 1 . The figure was made using
MOLSCRIPT [29], RASTER3D [30], and
SPOCK [31].
Results fined its structure at 1.8 A˚ resolution. The mutant struc-
ture is very similar to the wild-type, with an overall rms
difference of 0.28 A˚ for C atoms. We observed smallStructure of the I546V Mutant
The uncomplexed I546V mutant A1 domain crystallized conformational differences that are very similar to those
reported previously in a complex of the same mutantisomorphously with the wild-type domain, and we re-
The von Willebrand Factor A1-Botrocetin Complex
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Figure 2. Structure of the A1 Domain
Stereo C plot of the I546V mutant A1 do-
main, uncomplexed (dashed lines) and com-
plexed (solid lines) with botrocetin, with occa-
sional numbering. The mutation site is
indicated by a ball. The B-C turn is indi-
cated in bold.
with antibody NMC-4 [9], showing that the antibody vades the other domain. A seventh disulfide (Cys 80-
Cys 75) links the two loops.does not affect the structure of the mutant. Ile 546 is
buried close to the lower surface of the domain; in the Complex formation with vWF A1 has limited effect
on the structure of botrocetin. Individual C-type lectinmutant, an additional water molecule is inserted into the
hydrophobic core in a cavity created by the smaller domains superpose well, with an rms difference of 0.50 A˚
(C), while the overall difference is 1.0 A˚, arising from aside chain. Although a pathway is difficult to establish,
conformational changes appear to propagate to the tight small quaternary shift between the two lobes. Several
side chains reorient on binding the A1 domain, as ex-B-C turn at the edge between the “front” and “upper”
faces of the domain, a region implicated in GpIb binding pected. One notable difference is a loop (88-91), dis-
ordered in the uncomplexed structure, which becomes[5, 11, 12]. Here, the main chain peptide bond at Asp
560-Gly 561 is flipped; the side chain of His 563 also ordered on complex formation, forming a central part
of the A1-botrocetin interface (see below).adopts a different conformation, stacking against Tyr
565 (Figure 1).
We determined the structure of the mutant A1 domain
Architecture of the A1-Botrocetin Complex
in complex with botrocetin at 2.6 A˚ resolution. Structural
Botrocetin engages a pair of  helices and a turn (5,
changes in the A1 domain on complex formation are
6, andD-5) on the “right-hand” face of A1, consistent
small: the rms difference for main chain atoms is 0.45 A˚
with mutagenesis studies [12, 14, 15]. Botrocetin binds
(Figure 2). Differences are limited to: (1) the buried water
via a central region of its bi-lobed structure, with compa-
molecule at the mutation site is lost; (2) the peptide
rable contributions from the  (43%) and  (57%) sub-
plane between Asp 560 and Gly 561 flips back to a
units (Figure 3). Complex formation buries approxi-
conformation similar to that in the wild-type structure
mately 1600 A˚2 of accessible surface, a typical value for
(Figures 1A and 1C); the side chain of His 563 remains in
a Kd in the 10 nM range [16]. Three tyrosine residuesthe “mutant” position, although there is some evidence
that are unique to botrocetin play a prominent role in
from the electron density of an alternative conformation
the interface, packing against the main chain of the two
similar to the wild-type; (3) there are small movements
 helices of A1. Tyr 45 and Tyr 91 lie on insertions
of the main chain and larger movements of side chains
with no homolog in the other family members, while the
that make new intermolecular contacts at the botrocetin
third tyrosine, Tyr 96, is a serine in the other members.
binding site; and (4) the N-terminal arm (residues 502–
A number of leucines provide hydrophobic contacts
508) shifts by 1 A˚, causing the side chain of Phe 507 to
near the center of the interface, and two clusters of
pack more tightly into a pocket created by the disulfide
acidic residues form salt bridges to the predominantly
bond and side chains from helix 7. This results in a
basic face of A1 (Table 1). Mutations of these basic
shift of helix 7, as a rigid body, upward by about 0.5 A˚.
residues in A1 disrupt botrocetin binding, and the struc-
While this movement may arise from a crystal contact
ture shows that this arises from a direct effect on the
in the complex structure, it demonstrates at least the
interface.
potential for the transmission of conformational changes
The structures of both wild-type A1 and the I546V
from the lower surface, containing the gain-of-function
mutant A1 in complex with the inhibitory antibody
type IIb mutations, to the upper, ligand binding, surface.
NMC-4 have been reported previously [3, 9]. The anti-
body footprint on the A1 domain is remarkably similar
to that of botrocetin. Thus, the antibody engages A1Structure of Botrocetin
Botrocetin is a member of a family of snake venom primarily via the beginning of helix 5 and the interface
between 5 and 6. Moreover, the location and size ofproteins that bind proteins involved in blood coagula-
tion. The crystal structure of uncomplexed botrocetin the VH-VL dimer are similar to those of botrocetin (Figure
3B). Like botrocetin, NMC-4 induces only small changeswas recently determined [13]. It is a disulfide-linked het-
erodimer comprising two homologous chains,  and , in the A1 domain, but unlike botrocetin, it does not alter
the conformation of the B-C loop.which intertwine to form a bi-lobed molecule with overall
dimensions of 75  35  35 A˚3 . Each subunit has a The remarkably similar footprint and location of the
inhibitory antibody NMC-4, which presumably blocksC-type lectin fold comprising two  helices, five 
strands, and three disulfides, plus a long loop that in- binding by steric hindrance, places further constraints
Structure
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Figure 3. Structure of the A1-Botrocetin
Complex
(A) Stereo view (C tracing) of the complex.
The current model includes 199 residues from
502 to 700 of the mutant A1 domain, 133 (119)
residues of the  () subunits of botrocetin,
and 94 water molecules. There is no electron
density for the loop (residues 55–60 in the 
subunit). The A1 domain is in blue; the  and
 subunits of botrocetin are in pink and green,
respectively. Gain-of-function mutations are
shown as blue balls; loss-of-function muta-
tions are shown in red; loss of botrocetin
binding mutations are shown in yellow. The
I546V mutation site is shown as a green ball.
(B) Space-filling model of the complex with
mutation sites indicated; same view as in (A).
The NMC-4 antibody (VH-VL dimer) is shown
as a semitransparent molecular surface.
(C) Electrostatic surface potential contoured
from15 (red) to15 (blue) kT e1. The figure
was made using RASTER3D [30] and GRASP
[32].
on the binding surface. Adjacent to the upper surface of hydrodynamic shear stress by immobilizing wild-type
or mutant A1 and their complexes with botrocetin in athe A1 domain, botrocetin protrudes further than NMC-4
over the putative GpIb binding surface. Here, the  sub- parallel plate flow chamber (see Experimental Proce-
dures). In the absence of botrocetin, wild-type A1 hasunit of botrocetin presents a prominent  helix with a
ridge of acidic residues that extends the already acidic a pronounced shear threshold for promoting platelet
adhesion. This phenomenon is not unique to purifiedGpIb binding surface, and which could interact with a
basic surface on GpIb (Figure 3C). Adjacent to the B- platelets or recombinant proteins, as similar results are
C loop of A1, NMC-4 protrudes about 10 A˚ further than obtained with surface-immobilized plasma vWF or with
botrocetin, and it is here that NMC-4 may offer steric a perfusate consisting of anticoagulated whole blood
hindrance to binding. (Figures 4A and 4B). The requirement for a critical level
of hydrodynamic shear to promote GPIb-vWF-A1 inter-
actions is abolished in the type IIb mutant, which bindsPlatelet Adhesion under Flow
We studied the effects of botrocetin on A1-mediated platelets at all wall shear stress tested. Platelet translo-
cation velocities are also reduced in a similar mannerplatelet adhesion and translocation under conditions of
Table 1. Polar Interactions between the A1 Domain and Botrocetin
A1 Botrocetin Distance (A˚)
Salt bridges Arg 632 NH1 Glu 95 OE2 3.0
Arg 636 NH2 Glu 107 OE2 2.6
Gln 639 OE1 Lys 49 NZ 2.8
Arg 663 NH2 Asp 86 OD2 2.9
Arg 663 NH2 Asp 89 OD1 2.7
Lys 667 NZ Asp 89 OD1 2.9
Water-mediated
Wat 29 Gln 639 NE2 Asp 50 OD2 4.8
Wat 78 Arg 636 NE Asp109 OD2 6.0
Long-range ionic
Gln 628 NE2 Asp 70 OD2 4.5
Arg 632 NH1 Glu 107 OE1 3.8
Lys 642 NZ Asp 50 OD2 4.2
Gln 661 NE2 Tyr 91 OH 3.4
Arg 663 NE Asp 88 OD2 4.2
Gln 668 NE2 Tyr 45 OH 4.2
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Figure 4. Platelet Accumulation and Translo-
cation Velocities on vWF-A1 Substrates in
Flow
(A) Botrocetin treatment of vWF-A1 sub-
strates (1:3 molar ratio) and the type IIb muta-
tion I546V abolish the requirement for shear
stress-dependent platelet attachment. The
number of platelets that formed adhesions
after 5 min of flow was determined on the
indicated substrates as a function of wall
shear stresses. Similar levels of adhesion
were also observed with botrocetin at molar
ratios with vWF-A1 of 1:5 to 1:1 (data not
shown). Platelet interactions with surface-
immobilized plasma vWF yielded similar re-
sults (n 3). Data represent the mean	 stan-
dard error.
(B) A hydrodynamic threshold level of wall
shear stress exists for platelet tethering/
translocating on wild-type vWF-A1 during
perfusion of whole blood (n  3).
(C) Translocation velocity (m s1) of purified
platelets. Mean 	 standard error for 50–75
platelets from three independent experi-
ments performed in duplicate.
(Figure 4C). Recent kinetic analysis of bimolecular Discussion
GPIb interactions with the A1 domain revealed an
Our results show that botrocetin binds close to the GpIb6-fold lower value in dissociation rate constant (koff0)
binding surface (as mapped by mutagenesis), and doesfor the type IIb mutant I546V, compared to the wild-type
not switch the A1 conformation into a high-affinity state.domain (0.55 versus 3.45 s1), an alteration consistent
with the observed changes in platelet adhesion [17]. Our It therefore seems likely that botrocetin enhances GpIb
binding directly, either by augmenting the binding sur-current data thus suggest that botrocetin has a similar
effect on the kinetic properties of this receptor-ligand face or by enhancing the on-rate through electrostatic
attraction. The inhibitory antibody NMC-4 binds at a verypair as that observed for the type IIb mutation. Further-
more, the effect of botrocetin on the type IIb mutant is similar location, and has no effect on the conformation of
the wild-type or mutant domains. NMC-4 presumablyto enhance these effects further.
Structure
948
Table 2. Statistics for Data Collection and Refinement
Data collection
Data set I546V I546V-botrocetin
Wavelength (A˚) 1.08 0.989
Space group P61 P21
Cell dimensions (A˚) a  86.1, c  68.5 a  65.7, b  66.7, c  69.4,   105.4

Resolution (A˚) 100–1.8 (1.83–1.8) 100–2.6 (2.64–2.6)
Total reflections 63,116 49,341
Unique reflections 25,460 (1,012) 18,178 (594)
Completeness (%) 94.6 (76.7) 92.9 (62.5)
Rmerge (%)1 4.3 (31.5) 4.6 (20.7)
I/ 19.9 (3.2) 23.9 (5.2)
Refinement
Resolution (A˚) 6.0–1.8 (1.83–1.8) 6.0–2.6 (2.66–2.6)
Reflections (F  0) 22,850 14,512
R factor (%)2 18.8 (26.4) 21.9 (25.4)
Rfree (%)3 20.8 (26.7) 27.9 (27.4)
Nonhydrogen atoms
Protein 1,620 3,667
Water 233 94
Rms deviations
Bonds (A˚) 0.005 0.007
Angles (
) 1.28 1.32
Mean B factor (A˚2)
Protein 17.9 38.2
Water 28.4 33.0
1 Rmerge  |I  I|/|I|, where I is the intensity of an individual reflection and I is the average intensity of that reflection.
2 R factor  |Fo  Fc|/|Fo|, where Fo and Fc are the observed and calculated structure factors, respectively.
3 Rfree  R factor calculated using 5% of the reflection data selected randomly and omitted from the start of refinement.
Numbers in parentheses refer to the outer resolution shell.
inhibits binding by steric hindrance, consistent with its within the B-C loop, lead to defective GpIb binding
[14, 18], and that this defect is overcome by the bindingsimilar (but distinct) footprint and steric occlusion.
Comparison of the crystal structures of the type IIb of botrocetin. We suggest that botrocetin “rescues” the
activity of these mutants by stabilizing the wild-typemutant I546V with the wild-type domain reveals only
small conformational differences caused by the muta- conformation of the GpIb binding surface via its tight
binding to an adjacent surface.tion, in spite of a marked functional effect. Moreover, the
binding of botrocetin reverses most of these structural
differences, while enhancing the functional effect. Thus, Biological Implications
whatever the mechanism of affinity enhancement by
type IIb mutations may be, it appears to be independent vWF is required for hemostasis in capillaries where fast
blood flow creates high hydrodynamic shear forces thatof that of botrocetin, since the affinity of the A1-botro-
cetin complex is further enhanced by the type IIb muta- disrupt other mechanisms of blood coagulation. Under
the influence of hydrodynamic shear forces, immobi-tion. Within the model of Celikel et al., this behavior is
explained by the fact that botrocetin does not fully revert lized vWF gains the ability to bind to platelets via their
GpIb receptor, but the structural basis of this phenome-the mutant conformation to that of the wild-type struc-
ture; as noted in the Experimental Procedures, although non is unknown. Since the A1 domain of vWF recapitu-
lates the behavior of full-length vWF in vitro when immo-the majority of A1 domains in the botrocetin complex
have the wild-type conformation of the B-C peptide bilized on a solid support in a flow chamber, structural
studies of the recombinant A1 domain may illuminateplane, there is a minor proportion in the “mutant” confor-
mation. Within the two-state “integrin” model, the type the regulatory mechanisms of the full-length molecule.
A number of point mutations within the A1 domain createIIb mutation shifts the equilibrium between low- and
high-affinity states toward the latter, but the observed a “gain-of-function” phenotype (type IIb) in which regu-
lation is lost; this mutant vWF binds spontaneously to(low-affinity) conformation remains predominant and is
the one captured in the crystal lattice; botrocetin binding platelets in the absence of shear forces, leading to von
Willebrand disease. These mutation sites are distinctdoes not substantially affect the position of this equilib-
rium (the small conformational differences observed from the surface implicated in binding to GpIb, sug-
gesting that the affinity of the A1 domain is regulatedcrystallographically are unrelated), so that again the
functional effects are independent. Clearly, quantitative allosterically via conformational changes within the
domain.data on bimolecular interactions and/or the crystal
structure of the A1-GpIb complex are required to distin- We determined the crystal structures of one such
gain-of-function A1 domain (I546V) and its complex withguish between these models.
Finally, we note that a number of mutations to residues the snake venom protein botrocetin, which also acti-
vates vWF to bind platelets in the absence of shearon the upper surface of the A1 domain, including G561S
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) is observed. The final R factors (Rfree) are, for the uncomplexedforces. Botrocetin binds to a surface adjacent to the
mutant A1, 18.8% (20.8%) at 1.8 A˚ resolution, and for the complex,GpIb binding surface that has been mapped by muta-
21.9% (27.9%) at 2.6 A˚ resolution. All of the residues in both thegenesis, causing small conformational changes within
structures lie within allowed regions of the Ramachandran plot as
the mutant A1 domain that switch it toward the wild- defined by the program PROCHECK [27]. Data collection and refine-
type (low-affinity) conformation. We interpret these data ment statistics are summarized in Table 2.
to mean that botrocetin does not activate A1 allosteri-
cally, so it presumably works by augmenting the binding Platelet Accumulation and Velocity Measurements in Flow
Platelet adhesion to purified vWF-A1 was assessed in a parallelsurface for GpIb. Our studies of platelet adhesion under
plate flow chamber apparatus as previously described [5]. For ex-flow show that the functional effect of botrocetin binding
periments involving botrocetin, A1 domain proteins (3 M) wereis remarkably similar to that of the type IIb mutation.
preincubated with the purified snake venom (1:1 to 5:1 molar ratioMoreover, botrocetin further enhances the adhesive
of A1 to botrocetin) for 30 min at room temperature prior to absorbing
properties of the type IIb mutant, suggesting that the the complex to glass coverslips. Briefly, platelets purified from ci-
mechanisms of activation are independent. However, trated whole blood (5  107 per ml) were perfused over vWF-A1
proteins (100 g per ml coating concentrations) at shear stressesthe structural basis of affinity enhancement by type IIb
ranging from 0.2 dyn cm2 to 3 dyn cm2. Wall shear stress wasmutations remains unresolved.
calculated from the momentum balance on a Newtonian fluid, as-
suming a viscosity of 1.0 cP [28]. To evaluate the effect of red bloodExperimental Procedures
cells on platelet tethering, anticoagulated whole blood was perfused
through protein-coated microcapillary tubes (cross-section of 0.2Purification and Complex Formation
2.0 mm and a wall thickness of 0.15 mm) and the dynamics of plateletRecombinant vWF mutant A1 domain (I546V) was expressed in
interactions with the wild-type vWF-A1 substrate were viewed usingEscherichia coli, refolded and purified, and then subjected to limited
differential interference contrast (DIC) microscopy (Nikon X60, oil).proteolysis by chymotrypsin to remove an N-terminal sequence that
The wall shear rates were calculated as 0.03 poise  g based oninhibits crystal growth, as described for the wild-type domain [4].
the apparent viscosity of whole blood. Translocation velocities wereBotrocetin was purified from the crude venom of Bothrops jararaca
determined by subjecting cells that had tethered to wild-type, botro-(Sigma) using methods described previously [19–21]. The purified
cetin-treated, or mutant substrates to incremental increases in wallmutant A1 domain was incubated with botrocetin in 0.02 M Tris (pH
shear stress (from 3 dyn cm2 to 36 dyn cm2). An enzyme-linked8.0), 0.15 M NaCl for 30 min at room temperature. The binary com-
immunosorbent assay was utilized to ensure that equivalent concen-plex eluted as a single peak at the expected molecular weight of
trations of recombinant proteins were absorbed to glass coverslips52 kDa using a Superdex 200 column (Amersham Pharmacia Bio-
[5]. Platelet attachment and their subsequent motion were recordedtech). The purified complex was confirmed to contain each compo-
on Hi-8 videotape using a Nikon microscope with a plan 10 ornent of the binary complex by SDS-PAGE under reducing and nonre-
20 objective, respectively. Inhibition studies were performed byducing conditions.
preincubation of platelets with mAb 6D1 for 15 min at a final concen-
tration of 20 g/ml. A PC-based interactive image analysis system
Crystallization and Data Collection was used to quantitate the number of platelets attached per unit
Crystals of the uncomplexed mutant A1 domain were grown using area as well as translocation velocities.
the hanging drop vapor diffusion method at room temperature with
drops containing 2 l each of protein (5 mg ml1) and a reservoir
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